Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)

Trial Profile

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duvelisib (Primary) ; Ofatumumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms DUO
  • Sponsors Infinity Pharmaceuticals; Verastem Oncology
  • Most Recent Events

    • 06 Nov 2019 According to Verastem Oncology media release, data will be presented at the upcoming American Society of Hematology 2019 Annual Meeting.
    • 23 Oct 2019 According to a Verastem Oncology Media Release, data will be presented will be presented at the Lymphoma & Myeloma 2019 International Congress taking place October 23-26, 2019, in New York City.
    • 20 Sep 2019 According to a Verastem Oncology media release, three posters highlighting clinical data for COPIKTRA (duvelisib) from this study will be presented at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia (20th-23rd Sep 2019,Edinburgh, UK).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top